about
Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.Quality assurance for the EORTC 22071-26071 study: dummy run prospective analysis.Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review.EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach.Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicenter international setting.Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.Improved cone-beam computed tomography in supine and prone breast radiotherapy. Surface reconstruction, radiation exposure, and clinical workflow.Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials?Adaptive radiotherapy for locally advanced non-small cell lung cancer, can we predict when and for whom?Respiratory Motion, Anterior Heart Displacement and Heart Dosimetry: Comparison Between Prone (Pr) and Supine (Su) Whole Breast Irradiation.Feasibility evaluation of prone breast irradiation with the Sagittilt© system including residual-intrafractional error assessment.[Modern three-dimensional conformal craniospinal radiotherapy].Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925)Induced acute erythema and late pigmentation may not be correlated: in regards to Perera et al. (Int J Radiat Oncol Biol Phys 2005;62:1283-1290)[Conformal stereotactic radiosurgery therapy: plan evaluation methods and results]Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991Quality assurance of the EORTC 22043-30041 trial in post-operative radiotherapy in prostate cancer: results of the Dummy Run procedureInterobserver variability in delineation of target volumes in head and neck cancer
P50
Q33426202-44C9214B-03F9-4B7F-A5B5-B4FF6474BC48Q35030236-5EDC5308-D0AE-475A-9148-A7D154643CADQ37336206-C42B9385-13E7-4B3C-91B2-30213E4A4751Q37449362-9E6DA59C-144C-4E9A-B1EF-DFAB7539DB48Q37896839-F963B18E-70DF-472B-BF88-A52D93051AF4Q43105854-C29AF2F9-9E5C-4822-A6BA-1A7BCAB94C05Q44221620-9E5D39FE-B44F-48D7-BF46-0B884A59368CQ47415107-BFA2374D-DC3D-4D1F-90F8-F1F6927453F3Q49110946-0CAABE03-83B1-47D3-863E-5450B21C318CQ51643745-FD0A0406-ACF3-49DD-96EF-E95189C26326Q53064046-521834CF-D1BA-4380-9016-A692E6CB1936Q55462858-9738C9DA-81BC-4777-899D-27CD41808485Q82640877-E4C819D0-C44E-4445-B5FB-ED77E44ED0F0Q83161587-D5C3B44F-F424-4EDE-AA3B-6E307A3DDCF1Q84308762-FEBB1598-146C-437A-8DF4-7AD746EBD60EQ84408300-B6B3338B-C067-4402-9548-2D6A9D98E990Q86852345-91843D33-4E92-451A-A9D5-75FCA5AABC1CQ91708974-074CEE14-B739-47BD-8FEB-27945F397FBF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Akos Gulyban
@ast
Akos Gulyban
@en
Akos Gulyban
@es
Akos Gulyban
@nl
type
label
Akos Gulyban
@ast
Akos Gulyban
@en
Akos Gulyban
@es
Akos Gulyban
@nl
prefLabel
Akos Gulyban
@ast
Akos Gulyban
@en
Akos Gulyban
@es
Akos Gulyban
@nl
P106
P31
P496
0000-0002-6805-8802